Danaher Corporation
DHR
$219.81
+1.08%
Danaher Corporation is a global life sciences and diagnostics company that designs and manufactures scientific instruments, consumables, and diagnostic tests used in biopharmaceutical research, clinical laboratories, and applied markets. Following the late-2023 spin-off of its environmental and applied solutions unit, Veralto, Danaher has sharpened its identity as a pure-play healthcare platform, competing with the likes of Thermo Fisher, Sartorius, and Agilent in the high-margin tools and diagnostics arena. The current investor narrative centers on the company's aggressive M&A strategy, most notably the recently closed acquisition of Masimo's healthcare business, which management frames as a steady, financially accretive but conservative growth move rather than a transformative bet. At the same time, investors are debating whether a mid-2026 shipment delay in the biotech segment was a temporary hiccup or a sign of softening end-market demand, a debate that has driven sharp swings in the share price and left the stock down year-to-date even as it recovers from its spring lows.…
DHR
Danaher Corporation
$219.81
Related headlines
Investment Opinion: Should I buy DHR Today?
Danaher earns a Buy rating based on its strong buy analyst consensus (mean 1.44), 9.6% upside to the average target of $241.00, and a forward PE of 23.64x that sits below its historical average. The core thesis is that the company's high recurring revenue, robust cash flow, and discounted valuation relative to its own history provide a favorable risk/reward for long-term investors, despite near-term integration risks.
The supporting evidence is compelling: 83% of revenue is recurring, providing stability; TTM free cash flow of $5.466 billion comfortably covers dividends and investments; the balance sheet is strong with debt-to-equity of 0.35 and current ratio of 1.87; and the stock trades at a discount to its historical PE range (19x-65x). Additionally, the technical trend has turned positive, with the stock up 10.43% over three months, outperforming the S&P 500 by 7.30 percentage points. Analyst estimates for EPS of $12.48 and revenue of $33.86 billion imply confidence in the Masimo accretion story.
The biggest risks are integration challenges with Masimo, potential margin compression, and a slowdown in biotech demand. The rating would upgrade to a Strong Buy if forward PE compresses below 20x or if organic growth accelerates above 7%. It would downgrade to Hold if revenue growth decelerates below 4% or if gross margins fall below 55%. Relative to its history and peers, Danaher appears undervalued on a forward earnings basis, but the premium EV/EBITDA multiple suggests the market is already pricing in a successful integration. Overall, the stock is fairly valued with a slight upside bias, making it a solid long-term holding.
Sign up to view all
DHR 12-Month Price Forecast
Danaher presents a balanced risk/reward profile. The company's high-quality recurring revenue, strong cash flow, and discounted forward PE are attractive, but premium EV/EBITDA multiples and modest growth limit upside. The analyst consensus is bullish, but the wide target range ($200-$310) reflects uncertainty. I would upgrade to bullish if organic growth accelerates above 7% and margins stabilize, or downgrade to bearish if biotech demand weakens further and integration costs mount. The base case suggests a total return of 5-10% over 12 months, with the stock likely trading in the $230-$250 range.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $241.00 and implied upside of +9.6% versus the current price.
Average Target
$241.00
0 analysts
Implied Upside
+9.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $310
Analyst target range
Danaher is covered by 22 analysts, and the consensus is emphatically bullish: the recommendation is a strong buy with a mean rating of 1.44 on a scale where 1 is a strong buy and 5 is a sell. The average price target of $241.00 implies roughly 9.6% upside from the current price of $219.81, a modest but positive expected return that reflects the stock's recent run-up toward analyst fair value. The consensus EPS estimate of $12.48 for the forward year, against a forward PE of 23.64x, suggests analysts are modeling meaningful earnings recovery, and the estimated revenue average of $33.86 billion implies roughly 5-6% top-line growth. The bullish tilt is notable given the stock is still down year-to-date, indicating that analysts view the pullback as a buying opportunity rather than a warning sign. The target range is wide, spanning from a low of $200.00 to a high of $310.00, a $110 spread that signals meaningful disagreement about the company's trajectory. The high target of $310.00, roughly 41% above the current price, likely assumes successful Masimo integration, accelerating organic growth, and multiple expansion back toward historical highs, while the low target of $200.00, about 9% below the current price, appears to price in continued biotech shipment delays, margin compression, and a slower-than-expected recovery in instrument demand. Recent institutional ratings show a stable-to-improving pattern: in July 2026, Stifel, RBC Capital, Guggenheim, and TD Cowen all reiterated Buy or Outperform ratings, while Wells Fargo maintained Equal Weight, and the only notable downgrade in the past six months was Citigroup moving from Buy to Neutral in May 2026. The absence of any Sell ratings and the clustering of reiterations around the Q2 earnings date suggest that the analyst community is broadly aligned on the recovery thesis, though the wide target spread means individual conviction varies considerably.
Bulls vs Bears: DHR Investment Factors
The bull case rests on Danaher's premium quality franchise, strong recurring revenue, robust cash flow, and a discounted forward valuation relative to its own history, supported by a strong buy analyst consensus. The bear case highlights the stock's premium absolute multiples, recent margin compression, modest organic growth, and execution risk surrounding the Masimo acquisition and biotech shipment delays. Currently, the bull evidence appears stronger: the forward PE of 23.64x is below historical averages, free cash flow is robust, and the technical trend has turned positive with relative strength. The single most important tension is whether the Masimo acquisition will drive sufficient earnings accretion to justify the premium multiple, or whether integration challenges and soft end-markets will lead to multiple compression. How this resolves will likely determine whether the stock breaks above $242.80 or retests the $160.93 low.
Bullish
- Analyst consensus strong buy with upside: 22 analysts rate DHR a strong buy (mean 1.44), with an average target of $241.00 implying 9.6% upside from $219.81. The high target of $310.00 suggests 41% upside if Masimo integration exceeds expectations.
- Recurring revenue provides stability: Recurring revenue of $5.2 billion represents 83% of total revenue, creating a durable, high-visibility base. This mix supports premium margins and reduces cyclicality.
- Attractive forward valuation vs history: Forward PE of 23.64x is well below the 33.86x at end-2025 and the lower half of the historical 19x-65x range. PS ratio of 6.59x is near multi-year lows, suggesting a value opportunity if growth accelerates.
- Strong cash flow and balance sheet: TTM free cash flow of $5.466 billion comfortably covers the $283 million quarterly dividend and funds acquisitions. Debt-to-equity of 0.35 and current ratio of 1.87 indicate financial flexibility.
Bearish
- Premium valuation leaves little room for error: EV/EBITDA of 25.30x and EV/Sales of 7.03x are rich relative to 5.5% revenue growth. The market is pricing in flawless execution of the Masimo integration and a growth reacceleration.
- Margin compression and earnings volatility: Q2 2026 gross margin fell to 57.64% from 66.63% a year earlier, and net margin dropped to 13.89% from 17.29% in Q1 2026. Integration costs and mix shifts are pressuring profitability.
- Biotech shipment delay raises demand concerns: A mid-2026 shipment delay in the biotech segment caused a 12% weekly drop in July, highlighting vulnerability to end-market timing. If delays persist, 2027 revenue estimates could be at risk.
- Modest growth trajectory: Q2 2026 revenue grew 5.54% year-over-year, a deceleration from 6.9% in Q1. Organic growth remains mid-single-digit, and the Masimo deal is expected to be only modestly accretive.
DHR Technical Analysis
Danaher is in a recovery uptrend that has been building since the spring, with the shares up 7.50% over the past year and 15.93% over six months, though they remain down 4.60% year-to-date. At a current price of $219.81, the stock sits at roughly 72% of its 52-week range (low of $160.93, high of $242.80), meaning it has clawed back most of its earlier losses but has not yet reclaimed its highs. That positioning suggests improving momentum rather than overextension, leaving room to run before the stock tests the upper boundary of its range. Recent momentum is clearly accelerating: the shares are up 7.30% over the past month and 10.43% over three months, both well ahead of the S&P 500's 2.12% and 3.13% respective gains, producing relative strength of +5.18 and +7.30 percentage points. This short-term outperformance diverges from the negative 8.50-point relative strength over the past year, a classic pattern of a stock transitioning from laggard to leader as the market re-rates it off a depressed base. The 1-month gain of 7.30% versus the 1-year gain of 7.50% shows that nearly all of the past year's return has been generated in the last four weeks, confirming a sharp inflection in trend. Key technical levels are well defined: the 52-week low at $160.93 is the critical support zone, while the 52-week high at $242.80 is the resistance that must be cleared to confirm a new leg higher. A breakout above $242.80 would signal that the market has fully digested the biotech shipment disruption and is pricing in the Masimo accretion story, whereas a breakdown below $160.93 would invalidate the recovery and point to renewed fundamental concerns. With a beta of 0.797, Danaher is roughly 20% less volatile than the broader market, which means position sizing can be more aggressive for a given risk budget, but it also implies the stock may lag in a sharp risk-on rally.
Beta
0.80
0.80x market volatility
Max Drawdown
-33.1%
Largest decline past year
52-Week Range
$161-$243
Price range past year
Annual Return
+7.5%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | +7.3% | +1.9% |
| 3m | +10.4% | +3.9% |
| 6m | +15.9% | +12.1% |
| 1y | +7.5% | +19.2% |
| ytd | -4.6% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory is modestly positive but not spectacular: Q2 2026 revenue of $6.265 billion grew 5.54% year-over-year, a deceleration from the 6.9% growth implied by Q1 2026's $5.951 billion versus Q1 2025's $5.741 billion. The sequential pattern shows Q4 2025 revenue of $6.838 billion, Q1 2026 of $5.951 billion, and Q2 2026 of $6.265 billion, with the year-over-year comparison improving from Q1's 3.7% to Q2's 5.5%, suggesting the growth rate is stabilizing rather than collapsing. Within the revenue mix, recurring revenue of $5.2 billion dwarfs nonrecurring revenue of $1.065 billion, an 83/17 split that provides a durable, high-visibility base and is a key reason the market awards the stock a premium multiple. The investment case hinges on whether this mid-single-digit organic growth can be supplemented by the Masimo acquisition to push the top line toward the high single digits that analysts are modeling for 2027. Profitability remains robust: Q2 2026 net income was $870 million on a 13.89% net margin, while the trailing gross margin stands at 60.93% and the operating margin at 20.91%. However, margins have compressed from the prior year, with Q2 2026 gross margin of 57.64% down from Q2 2025's 66.63%, and net margin falling from 9.35% to 13.89% (though the prior-year quarter was distorted by a $537 million other-expense charge). The Q1 2026 gross margin of 60.34% and net margin of 17.29% were both healthier than Q2, indicating some quarter-to-quarter volatility, but the overall profitability profile remains solidly investment-grade for a life sciences tools company. The balance sheet is a source of strength: debt-to-equity is just 0.35, the current ratio is a healthy 1.87, and trailing free cash flow is $5.466 billion, which comfortably covers the $283 million in quarterly dividends and leaves ample room for the $9.843 billion of acquisitions completed in Q2 2026. Return on equity of 6.88% and return on assets of 3.95% are modest on a trailing basis, reflecting the dilutive effect of the large Masimo deal and integration costs, but the 82.5% free-cash-flow-to-operating-cash-flow conversion ratio and $1.534 billion in Q2 operating cash flow demonstrate that the core business generates cash reliably. The main financial risk is the $8.485 billion of debt repayment in Q2, which, while manageable given the cash generation, signals that leverage has risen to fund the acquisition and will need to be worked down over the coming quarters.
Quarterly Revenue
$6.3B
2026-06
Revenue YoY Growth
+5.5%
YoY Comparison
Gross Margin
57.6%
Latest Quarter
Free Cash Flow
$5.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Because Danaher is profitable, with Q2 2026 net income of $870 million and trailing EPS of $0.022 (distorted by one-time items), the PE ratio is the appropriate primary metric, though the trailing PE of 45.15x is inflated by acquisition-related charges and is less informative than the forward PE of 23.64x. The gap between the trailing and forward multiples is enormous, implying the market expects earnings to roughly double over the next twelve months as Masimo contributions ramp and integration costs fade, a highly optimistic but not implausible assumption given the consensus EPS estimate of $12.48. Investors should note that the PEG ratio of -9.26 is meaningless here because it is distorted by the near-zero trailing EPS base, so the forward PE is the cleaner lens. On a peer-relative basis, Danaher's forward PE of 23.64x compares favorably to the broader healthcare sector, though the stock's PS ratio of 6.59x and EV/EBITDA of 25.30x are premium multiples that reflect the company's high recurring-revenue mix and strong margins. The EV/Sales of 7.03x is rich relative to the 5.5% revenue growth rate, suggesting the market is paying up for quality and the Masimo optionality rather than for current growth. The premium is defensible given the 60.93% gross margin and 20.91% operating margin, which are top-tier for the diagnostics and research tools industry, but it leaves little margin for error if organic growth disappoints. Historically, Danaher's PE ratio has ranged from roughly 19x to 65x over the past several years, with the current forward multiple of 23.64x sitting in the lower half of that band and well below the 33.86x recorded at the end of 2025. The PS ratio of 6.59x is also near the low end of its historical range, which has spanned from about 21x to 34x on a quarterly basis, though that comparison is complicated by the Veralto spin-off. The takeaway is that Danaher is trading at a discount to its own recent history on both earnings and sales, which either represents a value opportunity if the Masimo integration succeeds or a warning that the market expects structural growth deceleration.
PE
45.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
Investment Risk Disclosure
Danaher's financial risks are moderate but rising. The debt-to-equity ratio of 0.35 remains conservative, but the company repaid $8.485 billion of debt in Q2 2026 to fund the $9.843 billion Masimo acquisition, signaling increased leverage. Free cash flow of $5.466 billion covers the $283 million quarterly dividend, but the payout ratio of 24.3% and dividend yield of 0.54% offer limited income support. Margin compression is a concern: Q2 2026 gross margin fell to 57.64% from 66.63% a year ago, and net margin declined to 13.89% from 17.29% in Q1 2026, partly due to integration costs and mix. Revenue growth is modest at 5.54% year-over-year, and any deceleration could pressure the premium valuation.
Market and competitive risks are significant given Danaher's premium valuation. The forward PE of 23.64x is below the historical average, but EV/EBITDA of 25.30x and EV/Sales of 7.03x are rich compared to peers, leaving little room for error. The beta of 0.797 indicates lower volatility than the market, but the stock is still sensitive to sector rotation and macroeconomic shifts. Competitive threats from Thermo Fisher, Sartorius, and Agilent could intensify, particularly in bioprocessing where demand has been uneven. Recent news highlights a 12% weekly drop in July 2026 due to biotech shipment delays, underscoring vulnerability to end-market timing. Additionally, the M&A environment is active, with Bio-Techne receiving a premium buyout offer, which could raise acquisition costs for Danaher's future deals.
In a worst-case scenario, a prolonged biotech funding drought, integration missteps with Masimo, and margin erosion could trigger a sharp re-rating. The 52-week low of $160.93 represents a 26.8% decline from the current price of $219.81, and the analyst low target of $200.00 implies a 9.0% downside. If the stock were to retest its 52-week low, investors could lose approximately 27% from current levels. A more severe scenario, such as a recession or significant competitive losses, could push the stock below $160, but the strong balance sheet and recurring revenue provide some downside support. The maximum drawdown over the past year was -33.11%, indicating that a decline of that magnitude is possible in adverse conditions.
FAQ
The key risks include: 1) Integration risk from the $9.843 billion Masimo acquisition, which could lead to margin pressure and execution challenges; 2) End-market risk, as evidenced by the mid-2026 biotech shipment delay that caused a 12% weekly drop; 3) Valuation risk, with EV/EBITDA at 25.30x leaving little margin for error if growth disappoints; and 4) Macro risk, as a beta of 0.797 still exposes the stock to sector rotation and economic downturns. Additionally, the debt-funded acquisition increased leverage, with $8.485 billion of debt repaid in Q2 2026. The most severe risk is a prolonged biotech funding drought, which could push the stock toward its 52-week low of $160.93.
Our 12-month forecast for Danaher includes three scenarios: a base case (55% probability) with a target range of $230-$250, assuming steady execution and mid-single-digit growth; a bull case (25% probability) targeting $280-$310, driven by successful Masimo integration and accelerating organic growth; and a bear case (20% probability) targeting $160-$200, if biotech demand weakens and integration stumbles. The most likely scenario is the base case, where the stock trades in line with the analyst average target of $241.00. Key assumptions include organic growth of 5-6%, Masimo accretion of $0.30-$0.40 to EPS, and stable gross margins around 58-60%.
Danaher's valuation is mixed: on a forward PE basis, it trades at 23.64x, which is below its historical average of 33.86x at end-2025 and the lower half of its 19x-65x range, suggesting undervaluation. However, EV/EBITDA of 25.30x and PS ratio of 6.59x are premium multiples relative to peers, reflecting the company's high margins and recurring revenue. The market is pricing in successful Masimo integration and a growth reacceleration, leaving little room for error. Compared to its own history, the stock is cheap on earnings but expensive on sales, implying that investors are paying for quality and future growth rather than current performance.
Danaher appears to be a good buy for long-term investors, given its strong buy analyst consensus (mean 1.44) and 9.6% upside to the average target of $241.00. The stock trades at a forward PE of 23.64x, below its historical average, and offers a robust 83% recurring revenue mix. However, the premium EV/EBITDA of 25.30x and recent margin compression (Q2 gross margin down to 57.64%) warrant caution. The biggest downside risk is a retest of the 52-week low of $160.93, representing a 27% decline. For risk-tolerant investors with a 2-3 year horizon, the risk/reward is favorable, but near-term volatility is likely.
Danaher is better suited for long-term investment due to its strong recurring revenue base, robust cash flow, and strategic M&A that requires time to integrate. The stock's beta of 0.797 indicates lower volatility, making it less ideal for short-term trading. The dividend yield of 0.54% is modest, so income is not a primary driver. Earnings visibility is good but not immune to quarterly fluctuations, as seen in the biotech shipment delay. A minimum holding period of 2-3 years is recommended to fully realize the benefits of the Masimo acquisition and potential multiple expansion. Short-term traders might find opportunities around earnings, but the risk/reward favors patient investors.